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y 9, 2013.his study sought to investigate the efﬁcacy and safety of catheter ablation for atrial ﬁbrillation (AF) in patients with
heart failure with preserved ejection fraction (HFPEF).Background AF is a precipitating factor for clinical deterioration of HFPEF.Methods Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV]
ejection fraction >50%). AF-free probability after catheter ablation and factors relating to maintenance of sinus
rhythm were investigated. LV strain and strain rate were assessed by echocardiography at baseline and over 12
months after ablation.Results During a 34  16-month follow-up period, single- and multiple-procedure drug-free success rates were 27%
(n ¼ 20) and 45% (n ¼ 33), respectively. Multiple procedures and pharmaceutically assisted success rate was 73%
(n ¼ 54). No major complications occurred during follow-up. Multivariate Cox regression analyses revealed that AF
type (other than long-standing persistent AF) and lack of hypertension were independently associated with
maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% conﬁdence interval [CI]: 1.03 to 3.17, p ¼ 0.04;
HR: 0.49, 95% CI: 0.24 to 0.96, p ¼ 0.04, respectively). LV systolic indices (LV ejection fraction, LV strain/strain rate
at systole) and diastolic indices (E/E0, ratio of LV strain rate at diastole with early transmitral ﬂow) were improved
only in patients maintaining sinus rhythm at follow-up.Conclusions Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and
pharmaceuticals in patients with HFPEF. However, the current study was a single-arm analysis; therefore, larger
randomized control studies are needed to verify the beneﬁt of AF ablation in this cohort. (J Am Coll Cardiol
2013;62:1857–65) ª 2013 by the American College of Cardiology FoundationA substantial number of patients with symptomatic heart
failure have a relatively preserved left ventricular ejection
fraction (LVEF) (1,2). Such patients with heart failure with
preserved ejection fraction (HFPEF) have high prevalence of
atrial ﬁbrillation (AF) ranging from 20% to 40% (1–3).
HFPEF is thought to have predominant anomalies of left
ventricular (LV) active relaxation and passive stiffness that
lead to impaired diastolic ﬁlling (4,5); therefore, AF may
facilitate the development or progression of heart failure by
causing a rapid ventricular rate and short ventricular ﬁllingFaculty of Medicine, University of Tsukuba,
reported that they have no relationships relevant
se.
3; revised manuscript received July 1, 2013,time that result in a reduced cardiac output. Besides LV
diastolic dysfunction, recent data demonstrated a primary
abnormality in left atrial (LA) function in HFPEF (6). AF
exaggerates LA dysfunction through LA remodeling and
loss of effective atrial contraction. Thus, AF is a conse-
quence as well as a precipitating factor for clinical deterio-
ration of HFPEF (3,7,8). Although prognosis of HFPEF is
not better than that of heart failure with reduced LVEF
(1,2), an effective management strategy for HFPEF remains
to be established (9). Efﬁcacy of catheter ablation (CA) for
AF has been conﬁrmed, and its favorable effect on patients
with heart failure with reduced LVEF has been reported
(10,11). However, data on the efﬁcacy and safety of CA in
patients with AF with concomitant HFPEF are lacking.
Accordingly, the present study aimed to investigate whether
AF elimination by CA is effective in patients with HFPEF.
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speckle tracking
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Study protocol. Between Sep-
tember 2005 and December 2011,
1,212 patients with symptomatic
drug-resistant AF were candidates
for CA in our institution. Of these
patients, 108 presented with heart
failure symptoms (pulmonary
edema, leg swelling, fatigue, or
dyspnea on exertion) despite
preserved LVEF (>50%) and
fulﬁlled the criteria of HFPEF
according to European Society
of Cardiology recommendations
(12). Thirty-four patients were
excluded because of signiﬁcant
heart valve disease, previous valve
surgery, lung or renal disease
(n ¼ 20), or because follow-up
data were unavailable (n ¼ 14).
Finally, this study comprised
74 patients with concomitant
HFPEF and AF. All patients
had at least 1 heart failure–
related hospitalization and were
screened for active ischemic heart
disease and noncardiac causes of
symptoms. Of the study pop-
ulation, 42 patients had sinus
rhythm (SR) restored by electricalin and Strain Rate of the LV
in and strain rate of the 6 individually colored segme
to LV peak systolic strain and strain rate, respectively
ly. AVC ¼ aortic valve closure.cardioversion before CA (SR pre-CA). AF continued in the
remaining 32 patients until CA (AF pre-CA). All patients
underwent transthoracic echocardiography just before CA.
Peripheral blood samples were taken just before the CA for
measurements of routine blood chemistry including esti-
mated glomerular ﬁltration rate (calculated as: 0.741 
175  age0.203  creatinine1.154[ 0.742 if female] ml/min/
1.73 m2), N-terminal pro–B-type natriuretic peptide
(Elecsys proBNP, Roche Diagnostics, Mannheim,
Germany) and atrial natriuretic peptide (MI02 Shionogi
ANP, Shionogi Inc., Osaka, Japan). We investigated
recurrence of AF over a 12-month follow-up period after
CA and then divided the patients into 2 groups based on AF
recurrence (AF post-CA group) and maintenance of SR (SR
post-CA group). During long-term follow-up, we investi-
gated changes of echocardiographic parameters including
LV strain/strain rate. Ethical approval of the present study
was obtained from the local review committee, and all
patients provided their written informed consent.
Transthoracic echocardiography. Two-dimensional images
were recorded with a Vivid 9 cardiovascular ultrasound systems
(GE Healthcare, Horten, Norway) equipped with a variable
frequency 2.5- to 5-MHz Doppler transducer. Each param-
eter was determined based on American Society of Echocar-
diography recommendations (13,14). LV end-diastolic volume
and LVEF were calculated by Teicholz methods. LV mass
was estimated by area-length formula. LA volume was
measured from the apical view with the biplane method of
disks. LA total emptying fraction was calculated as follows:
([maximum LA volume – minimum LA volume]/maximumnts and the mean value for all segments (dotted line) are shown in A and B,
, and SRIVR and SRE refer to LV peak strain rate during the isovolumetric relaxation
Table 1 Follow-Up Results and Complications (N ¼ 74)
Length of follow-up, months 34  16
Mean time to ﬁrst atrial arrhythmia
recurrence, days
171  79
Success rates
Single procedure without AAD 20 (27)
Multiple procedures without AAD 33 (45)
Multiple procedures with AAD 54 (73)
Complication rates
Major complications: stroke, tamponade,
atrioesophageal ﬁstula, PV stenosis
0 (0)
Minor complications 4 (5)
Groin hematoma 2 (3)
Post-procedural pulmonary edema 2 (3)
Values are mean  SD or n (%).
AAD ¼ antiarrhythmic drug; PV ¼ pulmonary vein.
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1859LA volume)  100. The peak velocities of early (E) and
late (A) transmitral ﬂow and deceleration time of E velocity
were recorded from the long-axis view by pulsed Doppler
echocardiography. Tissue Doppler imaging was used to
measure the mean value of early peak diastolic velocity (E0) at
the mitral annular septal and lateral corners.
Grayscale images of apical views were obtained with frame
rates over 80 Hz for strain analysis by 2-dimensional speckle
tracking echocardiography (2DSTE). Recordings were
processed with acoustic-tracking software (EchoPAC PCFigure 2 Flow Chart Illustrating the Study Population and Results of
The patients in the blue and red boxes were classiﬁed as the sinus rhythm (SR) post–ca
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation; HFPEF ¼ heart failure preserved ejectiversion 110.0.0, GE Healthcare) allowing off-line semi-
automated speckle-based strain analyses. Longitudinal LV
strain (Fig. 1A) and strain rate (Fig. 1B) were measured by
2DSTE as previously reported (15,16). Peak systolic strain/
strain rate (SISYS, SRSYS), peak strain rate during iso-
volumetric relaxation period (SRIVR) and early diastole
(SRE) were calculated by averaging the values of each of the
18 segments, which were derived from the 6 segments of
each of the 3 apical views (2-chamber, 4-chamber, and apical
long-axis views). Ratios of early mitral inﬂow (E) and SRIVR
and SRE have been shown to predict LV ﬁlling pressure
(15,16) and were, therefore, used as diastolic indices.
All measurements of heart structure and performance
were averaged over 3 cardiac cycles during SR. In AF
rhythm, an index beat, which was the beat after the nearly
equal preceding and pre-preceding intervals, was used for
each measurement (17).
Catheter ablation and post-procedural follow-up. All
antiarrhythmic drugs were discontinued for 5 half-lives
before the procedure, except for amiodarone, which was
discontinued for at least 6 weeks before. Our ablation
protocol has been extensively described elsewhere (18,19).
Brieﬂy, we performed extensive encircling pulmonary vein
isolation by a double-lasso technique. Two 7-F decapolar
ring catheters (Lasso, Biosense Webster, Inc., Diamond Bar,
California) were positioned at each pulmonary vein ostium,
and an 8-mm tip 7-F deﬂectable catheter (Ablaze, JapanCA
theter ablation (CA) group (n ¼ 54) and AF post-CA group (n ¼ 20), respectively.
on fraction.
Table 2 Baseline Characteristics and Clinical Outcome of Study Patients
Total
(N ¼ 74)
SR Post-CA Group
(n ¼ 54)
AF Post-CA Group
(n ¼ 20) p Value
Age at enrollment, yrs 65  7 65  7 66  8 0.809
Male 55 (74) 41 (76) 14 (70) 0.765
BMI, kg/m2 26.7  14.7 27.4  17.0 24.8  4.3 0.493
Blood pressure, mm Hg
Systolic 126  21 127  22 122  20 0.390
Diastolic 71  12 72  13 69  10 0.469
NYHA class
II 52 (70) 39 (72) 13 (65) 0.778
III 22 (30) 15 (23) 7 (35) 0.839
Hypertension 57 (77) 41 (76) 16 (80) 0.540
Diabetes mellitus 21 (28) 18 (33) 3 (15) 0.151
Dyslipidemia 42 (57) 33 (61) 9 (45) 0.292
Prior PCI or CABG 14 (19) 10 (19) 4 (20) 0.562
History of stroke 10 (14) 9 (17) 1 (5) 0.148
Obstructive sleep apnea 19 (26) 13 (24) 6 (30) 0.765
Smoking 33 (45) 24 (44) 9 (45) 1.000
Hemoglobin, g/dl 13.8  1.7 13.8  1.7 13.7  1.9 0.811
eGFR, ml/min/1.73 m2 64  16 62  14 68  23 0.301
NT-proBNP, pg/ml 601 [324–936] 600 [389–871] 592 [312–1,062] 0.41
ANP, pg/ml 72 [49–95] 70 [47–81] 77 [70–118] 0.24
Medication
ACE-I or ARB 58 (78) 41 (76) 17 (85) 0.188
Beta-blocker 53 (72) 38 (70) 15 (75) 0.779
Calcium-channel blocker 34 (46) 27 (50) 7 (35) 0.300
Diuretics 23 (31) 17 (31) 6 (30) 1.000
Digoxin 5 (7) 4 (7) 1 (5) 0.393
Statin 39 (53) 29 (53) 10 (50) 0.799
LV structure
LV end-diastolic
diameter, mm
48  6 48  6 46  6 0.157
LV end-systolic
diameter, mm
31  6 31  6 29  5 0.221
IVST, mm 10  2 10  2 10  2 0.721
PWT, mm 10  2 10  2 10  2 0.758
EDVI, ml/m2 90  21 92  22 85  20 0.199
LV mass index, g/m2 119  33 121  35 113  27 0.445
RWT 0.42  0.11 0.40  0.08 0.44  0.16 0.319
Values are mean  SD, n (%), or median [interquartile range]. The p value indicates statistical difference between SR post-CA group and AF post-CA
group.
ACE-I ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ANP ¼ atrial natriuretic peptides; ARB ¼ angiotensin II receptor blocker;
BMI ¼ body mass index; CA ¼ catheter ablation; CABG ¼ coronary artery bypass graft; EDVI ¼ end-diastolic left ventricular volume index; eGFR ¼
estimated glomerular ﬁltration rate; IVST ¼ interventricular wall thickness at end-systole; LV ¼ left ventricular; NT-proBNP ¼ N-terminal pro–B-type
natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention, PWT ¼ posterior wall thickness at end-systole;
RWT ¼ relative wall thickness; SR ¼ sinus rhythm.
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1860Lifeline Co., Tokyo, Japan) or a 7.5-F irrigation catheter
with a 3.5-mm distal electrode (ThermoCool, Biosense
Webster) was used for ablation. The endpoint of the
extensive pulmonary vein isolation was creation of extensive
ipsilateral bidirectional conduction block from the atrium to
the pulmonary veins and vice versa. If AF was sustained after
pulmonary vein isolation, additional ablation consisting
of linear ablation of the LA roof, superior vena cava isola-
tion, and/or ablation of continuous fractionated atrial elec-
trograms was performed. If AF did not terminate after the
additional ablation, SR was restored by transthoracic car-
dioversion (18,19). A caval-tricuspid isthmus line was also
created in all patients with conﬁrmation of bidirectional block.After discharge, the patients were followed at 2 to 4 weeks
after the CA and then every 1 to 3 months at the outpatient
clinic (18,19). At each visit, the patients underwent
a 12-lead electrocardiogram and questioning regarding any
arrhythmia-related symptoms. At 2 weeks and 1, 3, 6,
and 12 months after CA, we performed 24-h Holter
monitoring and portable electrocardiographic monitoring
(HCG-901, OMRON, Kyoto, Japan). These modalities
were also used anytime the patients reported palpitations.
If the electrocardiogram showed any episodes of AF or any
other atrial tachyarrhythmias lasting >30 s during the
follow-up, the patients were diagnosed as having recurrence
of AF. A blanking period of 3 months was applied, and
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period. If conduction gaps were present or if the pulmonary
veins were not isolated during the redo procedure, ablation
was performed according to the ablation scheme used during
the ﬁrst procedure. Successful CA was deﬁned as the
maintenance of SR without antiarrhythmic drug therapy
after procedures during follow-up excluding the blanking
period. All patients continued oral anticoagulation to
maintain an international normalized ratio of between 2.0 to
3.0 during the entire follow-up period.
Statistical analysis. Means are expressed with 1 SD for
continuous variables, and medians are presented with
interquartile range for skewed variables. Differences in
continuous variables were evaluated with Mann-Whitney U
test or unpaired t test as appropriate. A chi-square test or
Fisher exact probability test was used for comparison of
categorical variables as appropriate. Cox proportional hazard
regression models were used to evaluate the inﬂuence of the
explanatory variables on maintenance of SR. Univariate
analyses were performed with variables that might have an
effect on success of CA on the basis of previous studies
(18–21). Multivariate analyses were performed with variables
that were statistically signiﬁcant in the univariate analyses.
Because of the small number of patients who did not
maintain SR (n ¼ 20), there could be up to 2 predictors
without overﬁtting the multivariate Cox model. Therefore,
to establish this multivariate model, we selected 2 variables
(AF type and history of hypertension) that seemed to have
signiﬁcant effects on outcome compared with other variables
in the univariate analysis. Reproducibility of 2DSTE wasTable 3 Characteristics and Therapies of AF
Total
(N ¼ 74)
SR
Duration of AF before CA, yrs 7.3  7.2
Type of AF
Paroxysmal 23 (31)
Persistent 7 (9)
Long-standing persistent 44 (59)
AAD tried before CA, n 3  1
AAD before CA
Class I 57 (77)
Class III 37 (50)
Class IV 12 (16)
Restoration of SR pre-CA 42 (57)
Prevalence of additional ablation
Roof line 44 (59)
Superior vena cava isolation 20 (27)
Complex fractionated atrial
electrogram ablation
20 (27)
Repeated ablation 50 (68)
Heart rate, beats/min
Baseline 67  13
Follow-up 67  7
Length of follow-up, months 34  16
Values are mean  SD or n (%). The p value indicates statistical difference
Abbreviations as in Tables 1 and 2.tested in 20 randomly selected patients. A value of p < 0.05
was considered to be statistically signiﬁcant. All statistical
analyses were performed using SPSS software (version 16.0,
SPSS Inc., Chicago, Illinois).Results
Study population and outcomes of AF ablation. Follow-
up results and complications of CA are summarized in
Table 1 and Figure 2. During a mean follow-up period
of 34  16 months (range: 12 to 75 months), single-
and multiple-procedure drug-free success rates were 27%
(n ¼ 20) and 45% (n ¼ 33), respectively. The multiple
procedures and pharmaceutically assisted success rate was
73% (n ¼ 54). CA was successfully performed in all patients,
and no major complications occurred during follow-up.
Although there were a few minor complications (groin
hematoma and post-procedural pulmonary edema), all of
these patients made a full recovery. General characteristics,
serum markers, and LV structural parameters in patients
with maintenance of SR (SR post-CA group, n ¼ 54) and
patients with AF recurrence (AF post-CA group, n ¼ 20)
are listed in Table 2. No statistically signiﬁcant differences
were found in any of the baseline parameters between the 2
groups. Detailed data regarding characteristics of the
arrhythmia and therapies for AF are shown in Table 3. The
difference of AF duration between groups did not reach
statistical difference; however, the proportion of long-
standing persistent AF was greater in the AF post-CA
group than the SR post-CA group. The prevalence of SRPost-CA Group
(n ¼ 54)
AF Post-CA Group
(n ¼ 20) p Value
6.3  6.3 10.0  8.9 0.10
20 (37) 3 (15) 0.09
6 (11) 1 (5) 0.39
28 (52) 16 (80) 0.04
2  1 3  1 0.53
41 (76) 16 (80) 0.49
26 (48) 11 (55) 0.79
7 (13) 5 (25) 0.18
28 (52) 14 (70) 0.56
30 (56) 14 (70) 0.19
14 (26) 6 (30) 0.77
12 (22) 8 (40) 0.15
34 (63) 16 (80) 0.16
66  14 70  6 0.09
65  6 68  9 0.13
33  7 36  15 0.41
between SR post-CA group and AF post-CA group.
Table 4 Factors Related to Maintenance of SR After Ablation
Variables
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Age at enrollment,
per 1-yr increase
0.99 0.96–1.03 0.69
Duration of AF before CA,
per 1-yr increase
0.95 0.90–1.00 0.048
Type of AF* 1.87 1.07–3.27 0.03 1.81 1.03–3.17 0.04
Male 0.69 0.36–1.29 0.25
Hypertension 0.50 0.25–0.99 0.046 0.49 0.24–0.96 0.04
Obstructive sleep apnea 1.28 0.71–2.32 0.42
NT-proBNPyz 0.76 0.58–0.99 0.04
LA volume indexz 0.89 0.64–1.24 0.48
eGFRz 1.05 0.87–1.27 0.63
Maintenance of sinus rhythm is the dependent variable. *Other than long-standing persistent AF. yLogarithmically transformed skewed variables. zPer 1-SD increase.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LA ¼ left atrial; other abbreviations as in Tables 1 and 2.
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1862restoration by electrical cardioversion before CA was
comparable in the 2 groups, and it did not inﬂuence the
outcome of AF ablation. The prevalence of additional
ablation did not differ between the 2 groups. No signiﬁcant
differences in heart rate between baseline and follow-up
values were noted in either group.
Prediction of patients who maintained SR. The results of
the Cox proportional hazard regression analysis for main-
tenance of SR are summarized in Table 4. MultivariateTable 5 Echocardiographic Parameters in Patien
SR Post-CA Gro
(n ¼ 54)
LVEF, %
Baseline 67  7
Follow-up 69  7*
Mitral peak E-wave velocity, cm/s
Baseline 79  20
Follow-up 74  22
E/A ratio
Baseline, n ¼ 42 1.5  0.6 (n ¼
Follow-up, n ¼ 54 1.3  0.7 (n ¼
Deceleration time of E-wave, ms
Baseline 216  52
Follow-up 220  51
E0 , cm/s
Baseline 7.2  2.6
Follow-up 9.0  3.5y
E/E0 ratio
Baseline 11.2  3.7
Follow-up 9.6  3.0*
LA volume index, ml/m2
Baseline 43  14
Follow-up 38  16y
LA total emptying fraction, %
Baseline 27  13
Follow-up 36  14*
Values are mean SD. The p value indicates statistical difference between SR
follow-up were not available because of AF rhythm. *p < 0.01 versus basel
LVEF ¼ left ventricular ejection fraction; NA ¼ not available; other abbrevanalysis identiﬁed AF type (other than long-standing
persistent AF) and lack of hypertension to be indepen-
dently associated with maintenance of SR (hazard ratio
[HR]; 1.81, 95% conﬁdence interval [CI]: 1.03 to 3.17,
p ¼ 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p ¼ 0.04,
respectively).
Changes in echocardiographic parameters. Changes in
conventional echocardiographic parameters are summarized
in Table 5. In the SR post-CA group, LVEF increased andts With and Without Recurrence of AF
up AF Post-CA Group
(n ¼ 20) p Value
66  8 0.93
66  7 0.10
82  34 0.56
87  30 0.04
28) 1.6  0.8 (n ¼ 14) 0.65
54) NA NA
208  42 0.53
204  39 0.20
7.6  2.2 0.26
8.4  3.0 0.40
13.3  6.5 0.10
12.2  4.8 0.04
51  24 0.10
55  25 0.008
29  10 0.65
25  10 0.001
post-CA group and AF post-CA group. In AF post-CA group, E/A ratios at
ine; yp < 0.05 versus baseline.
iations as in Tables 2 and 4.
Figure 3 Changes in LV Function
LV strain and strain rate measurements in patients who maintained sinus rhythm (SR post-CA group) and patients with recurrence of AF (AF post-CA group). Plotted values are
mean  SD. SISYS (A) and SRSYS (B) are indices of LV systolic function, and E/SRIVR (C) and E/SRE (D) are indices of LV diastolic function. Abbreviations as in Figures 1 and 2.
Table 6 Reproducibility of Strain and Strain Rate Measurements
SISYS SRSYS SRIVR SRE
Intraobserver
Correlation
coefﬁcient
0.99 0.95 0.93 0.99
Mean absolute
percentage
error, %
7.8  7.7 8.1  5.6 9.6  6.1 5.7  5.1
Interobserver
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baseline values, in contrast to these parameters in the AF
post-CA group, which showed no change. LA total
emptying fraction improved and LA volume index was
reduced only in the SR post-CA group during follow-up.
Changes in LV strain and strain rate measurements are
illustrated in Figure 3. Each parameter at baseline was
comparable between the 2 groups. From baseline to follow-
up, SISYS and SRSYS, as indices of longitudinal systolic
function increased, and E/SRIVR and E/SRE, which reﬂect
LV ﬁlling pressure, signiﬁcantly decreased only in the SR
post-CA group.
Reproducibility. Reproducibilities of 2DSTE measure-
ments are listed in Table 6.Correlation
coefﬁcient
0.99 0.90 0.89 0.93
Mean absolute
percentage
error, %
10.1  13.9 10.3  8.5 13.2  7.9 9.9  7.7
SISYS ¼ average of peak LV strain at systole; SRSYS ¼ average of peak LV strain rate at systole;
SRIVR ¼ average of peak LV strain rate during isovolumetric relaxation period; SRE ¼ average of
peak LV strain rate at early diastole.Discussion
Efﬁcacy of AF ablation in patients with HFPEF. Nu-
merous previous studies have successfully applied AF abla-
tion to heart failure patients with reduced LVEF (10,11).
However, this is the ﬁrst study, to our knowledge, to presentthe efﬁcacy and safety of CA for AF in patients with
HFPEF. The type of AF in this study cohort mainly con-
sisted of persistent or long-standing persistent AF. In
comparison with published outcomes of CA that targeted
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1864persistent/long-standing persistent AF, recurrence-free
probability after treatment with a composite of multiple
procedures and antiarrhythmic drugs was almost similar;
however, drug-free success rate was relatively low in our
results (22,23). LV diastolic dysfunction, which is a key
feature of HFPEF, may aggravate LA remodeling and
contribute to the arrhythmogenic substrate and development
of AF (24,25); therefore, total AF cure without antiar-
rhythmic drugs in HFPEF patients may be more difﬁcult
than that in other populations. This idea might be supported
by the current results that long-standing persistent AF and
hypertension, which relate to diastolic dysfunction (25,26)
and heart failure (3,8), could predict AF recurrence. In
HFPEF patients with restrictive ventricular physiology, AF
reduces diastolic ﬁlling time, and loss of effective atrial
contraction adds an adverse inﬂuence on LV ﬁlling and
hemodynamics. Thus, patients with HFPEF may obtain
greater beneﬁt from rhythm control, in theory. Moreover,
our results showing lower complication rates than those of
previous reports (22,23) suggested the safety of AF ablation
in patients with HFPEF. Therefore, CA may be an effective
therapeutic option for patients with AF with concomitant
HFPEF, although further surveys are needed.
Improvements of cardiac function after AF elimination
in HFPEF. In this study, optimal rate control was achieved
before CA, and heart rate did not change signiﬁcantly
from baseline to follow-up in either group. Therefore,
improvement in cardiac function after CA may be more
related to maintenance of SR than to normalization of heart
rate. In patients with AF or HFPEF, longitudinal systolic
deformations are depressed as a sign of early LV systolic
dysfunction despite a normal LVEF (27,28). Because the
longitudinal ﬁbers mediating long-axis deformation are
located in the subendocardial region, longitudinal function
may be more vulnerable to pathological changes and overload
(29). Therefore, normalization of cardiac rhythm by CA
might have contributed to the reduced burden within the LV
and ameliorated longitudinal LV strain in the present study.
As regards LV diastolic function, patients who present with
isolated diastolic dysfunction but preserved LVEF are not rare
in AF populations (25). The current study revealed that
maintenance of SR improved diastolic indices (E/E0 ratio, E/
SRIVR, and E/SRE), which correlated well with LV end-
diastolic pressure in HFPEF (15). Besides improvements of
LV function, long-term maintenance of SR achieved recovery
of LA function, which has been recognized as a partial
pathophysiology of HFPEF (6). Collectively, our results
suggested that elimination of AF by CA might ameliorate
cardiac function even in HFPEF as it has already been
reported in heart failure with reduced EF (10,11).
Study limitations. A standard deﬁnition of HFPEF is
lacking, and difﬁculty in diagnosing HFPEF remains
a major limitation. However, our patients met widely used
criteria for HFPEF (12) and had features that closely match
patients with HFPEF in other published studies (1,5,7).
Twenty-four–hour Holter monitoring less effectively detectsasymptomatic recurrence of atrial arrhythmias than does
transtelephonic daily monitoring or implantable loop
recorders (30). However, follow-up strategy in our study is
in line with the methodology of previous studies investi-
gating outcomes after AF ablation in patients with heart
failure (10,11).Conclusions
Our results may suggest that AF patients with concomitant
HFPEF can be effectively and safely treated with
a composite of repeated CA procedures and pharmaceuti-
cals. However, this is a single-arm study; therefore,
randomized studies with larger populations and longer
follow-up are warranted to conﬁrm the efﬁcacy of AF
ablation in patients with HFPEF.Reprint requests and correspondence: Dr. Yoshihiro Seo,
Cardiovascular Division, Faculty of Medicine, University of Tsu-
kuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan. E-mail: yo-seo@
md.tsukuba.ac.jp.REFERENCES
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